Streptococcus Pneumoniae Serotype 4 Conjugate Vaccine
This is a monovalent pneumococcal conjugate vaccine targeting Streptococcus pneumoniae serotype 4. The vaccine consists of the capsular polysaccharide antigen from serotype 4 conjugated to CRM197 protein, a non-toxic mutant of diphtheria toxin, which serves as an immunological carrier. Conjugate vaccines like this one enhance immune response by linking polysaccharide antigens to protein carriers, making them effective at stimulating protective immunity.
A targeted pneumococcal vaccine using CRM197 protein conjugate technology to prevent serotype 4 Streptococcus pneumoniae infections.
Key facts at a glance
- RxNorm
- 798228
- Generic
- Streptococcus Pneumoniae Serotype 4 Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Prevnar 20, Vaxneuvance, Prevnar 13
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
This vaccine is designed to provide active immunization against invasive disease, pneumonia, or other infections caused by Streptococcus pneumoniae serotype 4. Such infections include bacteremia, meningitis, and community-acquired pneumonia.
The vaccine works by presenting the capsular polysaccharide antigen of S. pneumoniae serotype 4 conjugated to CRM197 protein. This conjugation converts a T-cell independent antigen (polysaccharide) into a T-cell dependent antigen, eliciting a stronger and more durable immune response with memory B-cell formation. The CRM197 carrier protein helps stimulate helper T-cell responses, improving antibody production and immunological memory, particularly important in young children.
As a conjugate vaccine, this formulation is particularly beneficial for populations with immature or compromised immune systems, such as infants and young children, who typically respond poorly to pure polysaccharide vaccines. Vaccination schedules and target populations would be determined by regulatory approvals and clinical guidelines for pneumococcal immunization. As with all vaccines, administration should follow established protocols regarding contraindications, precautions, and potential adverse reactions.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 30, 2026. · Read our editorial policy